Acute Dialysis Quality Initiative

ADQI was started in response to concerns about the quality of care delivered to patients with Acute Kidney Injury (AKI) based on published data demonstrating that AKI is associated with an unacceptably high mortality, and there is a wide practice variation in its diagnosis and management worldwide.

In order to address these issues, ADQI has adopted an evidence based methodology to develop consensus based recommendations for managing patients with AKI. The key goal of the ADQI process is to ultimately provide evidence based guidelines for the management of AKI. Consequently, we have initiated a series of conferences under the auspices of the Acute Dialysis Quality Initiative.

Biomarkers in AKI

The X ADQI conference is focused on “Biomarkers in AKI”. Renal dysfunction is common among the critically ill and injured. Acute kidney injury occurs in as many as 2/3 of patients admitted to the ICU and renal failure, severe enough to require RRT occurs in nearly 6%. In recent years, stakeholder consensus and research activity have highlighted the need to discover, validate, and use biomarkers to improve the prediction, early diagnosis, and evaluation of AKI, to improve management of this syndrome. Participants will review existing evidence and make recommendations for current practice and for future research.

Patrick Murray  Ravindra Mehta
The Tenth ADQI conference will utilize the same format and methodology employed previously (www.adqi.net). Specifically, recommendations will be evidence-based and consensus driven.

Prior to the conference, participants will be organized into small groups and will systematically gather the evidence in the literature on each topic. Each sub-group will be responsible for defining the specific questions that will be addressed for each topic and presenting key evidence to the group.

**CONFERENCE STRUCTURE**

The specific objectives for this conference are:

- To develop a series of consensus statements on the discovery, validation, and clinical use of biomarkers in Acute Kidney Injury. The features of this methodology include:
  - Pre-conference evidence abstraction
  - Identification of key questions
  - Assessment of the available evidence
  - Plenary sessions to present evidence appraisal
  - Iterative refining of recommendations
  - Draft summary statements for each topic
  - External peer review of statements

- The primary focus of this meeting will be on diagnostic and prognostic evaluation of AKI focused on:
  - Use of biomarkers for risk assessment, early diagnosis and staging of AKI
  - Use of biomarkers for differential diagnosis of AKI in clinical practice
  - Use of biomarkers to assess prognosis and guide management of AKI
  - Imaging and other biomarkers for AKI

**PROGRAM**

**Tuesday, Aug 30**
400- 500pm Registration
500 pm- 700 pm
- Welcome and Introduction to ADQI X
- Methodology and “Ground Rules”
- Biomarkers in AKI: Current Status
- Preview of Questions

700-800 pm Dinner

**Wednesday, Aug 31**
7:30am Breakfast
8:00am Plenary I: group leaders present questions
10.00am Coffee/Tea break
10:15am Breakout Session I
12.30pm Lunch
1.30pm Plenary II: refined questions
3.00pm Breakout Session II
5.00pm Adjourn
6.00pm Dinner and Trinity visit

**Thursday, Sep 1**
7:30am Breakfast
8:00 am Plenary II: draft statements
10:30am Coffee/Tea Break
10:45am Breakout Session III
12:30pm Lunch
1:30pm Plenary III: final statements
3:00 pm Coffee/Tea Break
3.15pm Plenary III (continued)
4.15pm Adjourn for sightseeing
7:00pm Dinner

**Friday, Sept 2**
Departures

**Venue:** Herbert Park Hotel, Dublin, Ireland

**FACULTY**

**Chairpersons:**
- Patrick Murray (Ireland)
- Ravindra Mehta (USA)

**ADQI Council Members**
- John Kellum (USA)
- Claudio Ronco (Italy)
- Rinaldo Bellomo, Melbourne, Australia, President
- Ravindra Mehta (USA)

**Faculty**

- Group 1: Use of biomarkers for risk assessment, early diagnosis and staging of AKI
  - Facilitators: Andrew Shaw (USA); Claudio Ronco (Italy)
  - Members: Michael Haase (Germany), Peter McCullough (USA), Josee Bouchard (Canada), Sus Waikar (USA), Eddie Siew (USA)

- Group 2: Use of biomarkers for differential diagnosis of AKI in clinical practice
  - Facilitators: Zoltan Endre (Australia), John Kellum (USA)
  - Members: Stuart Goldstein (USA), Jay Koyner (USA), Etienne Macedo (Brazil), Kent Doi (Japan), Salvatore Di Somma (Italy)

- Group 3 Use of biomarkers to assess prognosis and guide management of AKI
  - Facilitators: Mink Chawla (USA), Dinna Cruz (Italy)
  - Members: Alan Maisel (USA), Andy Lewington (UK), Ravi Thadhani (USA), Sean Bagshaw (Canada), Raj Chakravarthi (India)

- Group 4 Imaging and other biomarkers for AKI
  - Facilitators: Can Ince (Netherlands), Mark Okusa (USA)
  - Members: Jacques Duranteau (France), Peter Doran (Ireland), Li Yang (China), Bertrand Jaber (USA), Shane Meehan (USA)

- Special Observers (Rotating Groups)
  - **Group A:** Paul Clopton (USA), Joe Bonventre (USA)
  - **Group B:** Paul Kimmel (USA), Bruce Molitoris (USA)
  - **Group C:** Prasad Devarajan (USA), Maria Fitzgibbon (Ireland)
  - **Group D:** Eisei Noiri (Japan), Chirag Parikh (USA)